InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,408.42
(
-1.73%
)
US TECH 100
17,947.60
(
0.00%
)
Dow Jones
40,345.41
(
-1.01%
)
Brent Oil
71.80
(
0.36%
)
Bitcoin
54,949.75
(
0.17%
)
Post# of 253062
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 838
Posts 120392
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 203134

Saturday, 08/06/2016 2:46:55 PM

Saturday, August 06, 2016 2:46:55 PM

Post# of 253062
Intriguing tidbit from RVNC 2Q16 PR/CC (#msg-124322727):

As to a second therapeutic indication for RT002, we plan to initiate a new U.S. Phase II trial later this year.

We'll be providing more detail on this exciting, novel indication along with the study design as soon as we initiate patient dosing.

The word, therapeutic in the above excerpt means non-cosmetic—i.e., cervical dystonia is the first therapeutic indication for RT002, and glabellar lines is a cosmetic (not therapeutic) indication.

On the 2Q16 CC, CEO Dan Browne said the mystery indication is something for which no botulinum toxin is currently approved. I’ll hazard a guess about what this new indication is after I’ve had some time to think it over.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up